• Ignacio Roy, Lorena Malagon, Javier Martínez, Javier Romero, Aitziber Munarriz, and Nuria Basterra.
• Cardiología, Área Clínica del Corazón, Complejo Hospitalario de Navarra, Pamplona, España. Electronic address: iroy.md@gmail.com.
• Med Clin (Barc). 2021 Nov 26; 157 (10): 459-463.

Introduction And Objectivesimplantable cardiac defibrillator (ICD) has been established as a therapy for malignant ventricular arrhythmias in patients at high risk of suffering them. Some studies suggest a possible relationship between the development of cancer and some prosthetic materials. Likewise, some investigations describe a higher incidence of cancer in patients with an ICD that suggest a potential relationship.MethodsRetrospective cohort study of patients that underwent implantation of an ICD in the Complejo Hospitalario de Navarra between 2000 and 2016. The follow-up finished in June 2018. Sociodemographic, comorbidities and oncological data was analysed. Cancer incidence rates were estimated and compared with the general population data and with data of a cohort of patients with reduced LVEF heart failure. Risk of cancer models were adjusted by competitive risk models.Results497 patients were included, mostly male (89.1%), with a mean age of 59.98 (14.98) years and a proportion of smokers of 67.6% and of ischaemic heart disease of 51.6%. The cancer incidence rate in the sample was 1230.9 per 100.000 person-year. In our study, features associated with cancer were older age, higher tobacco use and ischaemic cardiopathy.ConclusionsIn our sample of ICD carriers the incidence of cancer is high. This finding mainly seems to be related to tobacco usage and higher age.Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

27 keywords...

hide…